56% Increase in C. diff Due in Part to Improved Detection Hospitals that switched Clostridium difficile testing from nonmolecular to molecular methods recorded a 56 percent increase in recorded C.

Clostridium difficile infection is one of the most common healthcare-associated infections in adults in the United States. Older Americans are especially vulnerable to CDI, 2 and this infection has ...

Singulex’s Clarity C. diff toxin A/B assay, a rapid C. diff toxin test, has made its commercial debut, the company announced. “The Clarity toxin A/B assay offers a new approach to testing for C. diff ...

Infection with the pathogen Clostridium difficile is a significant source of healthcare-associated infections and estimated to account for 12 percent of all HAIs in the U.S.1 C. diff infection is the ...

Arlington, Va. — June 27, 2024 — A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C.

After the first year of interventions at Emory Saint Joseph's Hospital, there was a 63% decrease in hospital-onset C. diff cases as compared to the two years prior. Through a series of interventions ...

Add Yahoo as a preferred source to see more of our stories on Google. Consumer Reports has no financial relationship with advertisers on this site. Antibiotics treat infections, but surprisingly, they ...

On September 29, 2017, the U.S. Environmental Protection Agency (EPA) announced the availability of two final test method Standard Operating Procedures (SOP) for evaluating the efficacy of ...

A new study published today in the American Journal of Infection Control (AJIC) suggests that allowing bedside nurses to independently order testing for C. difficile significantly decreased the amount ...

DEAR DR. ROACH: I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing diarrhea on and off. I initially spoke to my general physician, and he ...

Pfizer's preventative vaccine against Clostridium difficile has passed a phase 2 test and will start registration studies in the next few months, in hot pursuit of a rival candidate from Sanofi.

Dear Dr. Roach: I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing diarrhea on and off. I initially spoke to my general physician, and he ...